| Cosmetic Dermatology |
1 |
1 |
| Skin Care |
0 |
0.95 |
| Pain Management |
0 |
0.75 |
| Analgesia |
0 |
0.99 |
| Aesthetic Medicine |
0 |
0.9 |
| Wound Management |
0 |
0.85 |
| Antibiotics |
0 |
0.19 |
| Biologic Therapy |
0 |
0.19 |
| Hypertension |
0 |
0.19 |
| Wound Healing |
0 |
0.8 |
| Antihypertensive Agents |
0 |
0.88 |
| Dermatitis |
0 |
0.15 |
| MRSA |
0 |
0.14 |
| Staphylococcal Infection |
0 |
0.13 |
| Toxicology |
0 |
0.13 |
| Antibacterial Agents |
0 |
0.12 |
| Cosmetics |
0 |
0.12 |
| Staphylococcus Aureus Infection |
0 |
0.12 |
| Electronic Health Record (EHR) and Healthcare Technology |
0 |
0.07 |
| Fungal Infection |
0 |
0.07 |
| Lipids Management |
0 |
0.07 |
| Revenue and Practice Management |
0 |
0.07 |
| Cosmeceuticals |
0 |
0.7 |
| Angiogenesis |
0 |
0.06 |
| Atopic Dermatitis |
0 |
0.06 |
| Botox |
0 |
0.06 |
| Candida |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Drug Development |
0 |
0.06 |
| Escherichia coli |
0 |
0.06 |
| Face |
0 |
0.06 |
| Medical Innovations |
0 |
0.06 |
| Medical Literature |
0 |
0.06 |
| Muscle |
0 |
0.06 |
| New York |
0 |
0.06 |
| Private Practice |
0 |
0.06 |
| Pseudomonas Aeruginosa Infection |
0 |
0.06 |
| Receptors |
0 |
0.06 |
| Wasting |
0 |
0.06 |